Brought to you by 
Baxter, Kuros Biosurgery in tissue repair deal; then Kuros regains rights to most candidates
Dec 2005
Executive Summary
Baxter's biosurgery business is entering the orthobiologics market. It has licensed exclusive worldwide rights to develop and market a portfolio of bone and soft tissue repair products that will use the company's Tisseel fibrin biomatrix in combination with biologic agents and related binding technology that were invented by Kuros Biosurgery AG.
Deal Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter, Kuros Biosurgery in tissue repair deal; then Kuros regains rights to most candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice